Loading clinical trials...

A Study to Evaluate the Safety of Remsima® SC in the Treatment of RA, AS, PsA and Ps | Clinical Trials | Clareo Health

RECRUITING

A Study to Evaluate the Safety of Remsima® SC in the Treatment of RA, AS, PsA and Ps

An Observational, Prospective Cohort Study to Evaluate Safety of Remsima® Subcutaneous in Patients With Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis and Psoriasis

NCT05866614•Celltrion

View on ClinicalTrials.gov

Summary

This is an observational, prospective cohort study to evaluate the safety of Remsima® SC in the treatment of RA, AS, PsA and Ps.

Detailed Description

CT-P13(Remsima®) is an IgG1 chimeric human-murine mAb biosimilar to Remicade® (infliximab, Janssen Biologics B.V.) developed by CELLTRION, Inc.The purpose of this study is to assess the safety of Remsima® Subcutaneous (SC) in Rheumatoid Arthritis (RA), Ankylosing Spondylitis (AS), Psoriatic Arthritis (PsA) and Psoriasis (Ps) patients by evaluation of adverse events of special interest (AESI)

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•a.Patients with active RA having inadequate response to disease modifying antirheumatic drugs (DMARDs), including methotrexate (MTX) or b.Patients with severe, active and progressive RA not previously treated with MTX or other DMARDs c.Patients with severe, active AS who have responded inadequately to conventional therapy or d.Patients with active and progressive PsA when the response to previous DMARDs has been inadequate or e.Patients with moderate to severe plaque Ps who failed to respond to or who have a contraindication to, or are intolerant to other systemic therapy including cyclosporine, methotrexate or psoralen ultra-violet A.
•The Remsima® SC group will include all patients who meet one of the following classification at the time of enrolment:
•1. Biologic-naïve patients or
•2. Patients continuing on infliximab IV including Remsima® IV who will switch to Remsima® SC or
•3. Patients continuing on biologic treatments other than infliximab who will switch to Remsima® SC or
•4. Patients continuing on Remsima® SC (having commenced Remsima® SC treatment prior to enrolment)
•The Remsima® IV group will include all patients who meet one of the following classification at the time of enrolment:
•1. Biologic-naïve patients or
•2. Patients continuing on biologic treatments other than infliximab who will switch to Remsima® IV or
•3. Patients continuing on infliximab IV including Remsima® IV who will switch to or maintain Remsima® IV \* Note: Switching from Remsima® SC to Remsima® IV is not allowed.

Exclusion Criteria

•1. Patients with a history of hypersensitivity to murine, chimeric, human, or humanized proteins or any of the excipients of Remsima® SC or Remsima® IV, whichever the patients are going to be treated in each treatment group, listed in the Summary of Product Characteristics (SmPC) of each product.
•2. Patients with any reported contraindications for Remsima® SC or Remsima® IV according to the SmPC of each product.
•1. Patients with active tuberculosis (TB)
•2. Patients with inactive (latent) TB who are not willing or not compliant with TB prophylaxis or a past diagnosis of TB without sufficient documentation of complete resolution following treatment.
•3. Patients with severe infection such as sepsis, abscesses and opportunistic infections (including, disseminated herpes simplex virus, candidiasis but not limited to)
•4. Patients with a current or past history of chronic infection with human immunodeficiency virus (HIV), hepatitis B and hepatitis C
•5. Patients with moderate or severe heart failure (New York Heart Association \[NYHA\] class III/IV)
•6. Patients for whom there are investigator concerns about treatment with tumour necrosis factor alpha (TNF-α) inhibitor, such as a history of any malignancy within the previous five years prior to enrolment, may be excluded at the investigator's discretion.

Locations (1)

CHU Purpan Hôpital Pierre Paul Riquet

Toulouse, France

Key Dates

Start Date

January 13, 2023

Primary Completion Date

March 1, 2027

Completion Date

March 1, 2027

Last Updated

August 22, 2024

Enrollment

864

ESTIMATED participants

Conditions

Rheumatoid ArthritisAnkylosing SpondylitisPsoriatic ArthritisPsoriasis

Interventions

Remsima IV

DRUG

Remsima SC

DRUG

Contacts

YounJeong Choi

CONTACT

+82 032 850 5767 younjeong.choi@celltrion.com

A Study of Picankibart in Patients With Active Psoriatic Arthritis

NCT07295509

Psoriatic Arthritis

View study

RECRUITING

Clinical Cohort Construction and Therapeutic Effect Evaluation of Integrated Traditional Chinese and Western Medicine in the Treatment of Rheumatoid Arthritis

NCT07484243

Rheumatoid Arthritis (RA)Rheumatoid Arthritis-Associated Interstitial Lung Disease+1 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: August 22, 2024Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

A Study to Evaluate the Safety of Remsima® SC in the Treatment of RA, AS, PsA and Ps

Inclusion Criteria

Exclusion Criteria

A Study of Picankibart in Patients With Active Psoriatic Arthritis

Clinical Cohort Construction and Therapeutic Effect Evaluation of Integrated Traditional Chinese and Western Medicine in the Treatment of Rheumatoid Arthritis

A Study to Evaluate the Safety and Activity of SAR448501/DR-0201 in Patients With Autoimmune Rheumatic Diseases

Targeted Remotely-delivered Anti-inflammatory Interventions With Exercise for Rheumatoid Arthritis

Plant-Based Diet for Patients With Rheumatoid Arthritis

A Phase II Trial of SHR-3045 Injection in Patients With Rheumatoid Arthritis